Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation

NCT06324266 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Newly Diagnosed Multiple Myeloma

Interventions

DRUG: Cyclophosphamide
DRUG: Lenalidomide

Sponsor

Jinling Hospital, China